Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5121691 | 1.00 | F2R (0.43) | F2RMEN1KMT2ATSHRHPGD | |
| SCHEMBL5116572 | 0.86 | LMNA (0.45) | MEN1KMT2ATSHRHPGDMAPT | |
| SCHEMBL5116566 | 0.86 | LMNA (0.45) | MEN1KMT2ATSHRHPGDMAPT | |
| SCHEMBL5125412 | 0.86 | F2R (0.43) | F2RMEN1KMT2ATSHRHPGD | |
| SCHEMBL5125411 | 0.86 | F2R (0.43) | F2RMEN1KMT2ATSHRHPGD | |
| SCHEMBL3492881 | 0.82 | ALDH1A1 (0.48) | MEN1KMT2ATSHRMAPTGAA | |
| SCHEMBL3492883 | 0.82 | ALDH1A1 (0.48) | MEN1KMT2ATSHRMAPTGAA | |
| SCHEMBL6218131 | 0.77 | TSHR (0.47) | F2RMEN1KMT2ATSHRHPGD | |
| SCHEMBL6218130 | 0.77 | TSHR (0.47) | F2RMEN1KMT2ATSHRHPGD | |
| SCHEMBL5126431 | 0.74 | LMNA (0.46) | MEN1KMT2ATSHRHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161573-A1 | PROCESS FOR THE PREPARATION OF IMIQUIMOD AND INTERMEDIATES THEREOF | DIPHARMA S.P.A. (IT) | 2008-07-03 | — | — | US | disclosed |
| US-7301027-B2 | Process for the preparation of Imiquimod and intermediates thereof | DIPHARMA S.P.A. (IT) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161573-A1 | PROCESS FOR THE PREPARATION OF IMIQUIMOD AND INTERMEDIATES THEREOF | MYD88, TLR7, MAVS | F2R 2463/4885MEN1 3676/4885KMT2A 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.